Synapse - TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy Journal Article

Authors:	Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; Lewis, N. E.; Zelenetz, A. D.; Palomba, M. L.; Matasar, M. J.; Noy, A.; Hamilton, A. M.; Hamlin, P.; Caron, P. C.; Straus, D. J.; Intlekofer, A. M.; Batlevi, C. L.; Kumar, A.; Owens, C. N.; Sauter, C. S.; Falchi, L.; Lue, J. K.; Vardhana, S. A.; Salles, G.; Dogan, A.; Schultz, N. D.; Arcila, M. E.; Horwitz, S. M.
Article Title:	TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
Abstract:	Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curativeintent chemotherapy. Recent molecular data have assisted in prognosticating these PTCLs, but most reports lack detailed baseline clinical characteristics and treatment courses. We retrospectively evaluated cases of PTCL treated with CHOP-based chemotherapy that had tumors sequenced by the Memorial Sloan Kettering Integrated Mutational Profiling of Actionable Cancer Targets next-generation sequencing panel to identify variables correlating with inferior survival. We identified 132 patients who met these criteria. Clinical factors correlating with an increased risk of progression (by multivariate analysis) included advanced-stage disease and bone marrow involvement. The only somatic genetic aberrancies correlating with inferior progression-free survival (PFS) were TP53 mutations and TP53/17p deletions. PFS remained inferior when stratifying by TP53 mutation status, with a median PFS of 4.5 months for PTCL with a TP53 mutation (n = 21) vs 10.5 months for PTCL without a TP53 mutation (n = 111). No TP53 aberrancy correlated with inferior overall survival (OS). Although rare (n = 9), CDKN2A-deleted PTCL correlated with inferior OS, with a median of 17.6 months vs 56.7 months for patients without CDKN2A deletions. This retrospective study suggests that patients with PTCL with TP53 mutations experience inferior PFS when treated with curative-intent chemotherapy, warranting prospective confirmation. © 2023 by The American Society of Hematology.
Journal Title:	Blood Advances
Volume:	7
Issue:	17
ISSN:	2473-9529
Publisher:	American Society of Hematology
Date Published:	2023-09-12
Start Page:	5172
End Page:	5186
Language:	English
DOI:	10.1182/bloodadvances.2023009953
PUBMED:	37078708
PROVIDER:	scopus
PMCID:	PMC10480533
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171631350&doi=10.1182%2fbloodadvances.2023009953&partnerID=40&md5=68e0cd2e01d7f619ea22ed512f181bed
Notes:	Article -- Source: Scopus